Share Name Share Symbol Market Type Share ISIN Share Description
Proteome LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 3.55p 0 08:50:20
Bid Price Offer Price High Price Low Price Open Price
3.40p 3.68p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.4 -2.1 -0.9 - 10.46

Proteome (PRM) Latest News

More Proteome News
Proteome Takeover Rumours

Proteome (PRM) Share Charts

1 Year Proteome Chart

1 Year Proteome Chart

1 Month Proteome Chart

1 Month Proteome Chart

Intraday Proteome Chart

Intraday Proteome Chart

Proteome (PRM) Discussions and Chat

Proteome Forums and Chat

Date Time Title Posts
22/6/201822:26Proteome Sciences leading Alzheimer's technology.79,037
15/6/201809:30Proteome, what next? (moderated)54,055
28/11/201711:40Only worth 3p on fundamentals....7
30/10/201721:22The Friends of Richards thread66
05/6/201715:59The useful PRM thread9

Add a New Thread

Proteome (PRM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Proteome trades in real-time

Proteome (PRM) Top Chat Posts

Proteome Daily Update: Proteome is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome was 3.55p.
Proteome has a 4 week average price of 3.22p and a 12 week average price of 3.10p.
The 1 year high share price is 5p while the 1 year low share price is currently 2.70p.
There are currently 294,648,723 shares in issue and the average daily traded volume is 97,359 shares. The market capitalisation of Proteome is £10,460,029.67.
saul goodman: Hahahahahaha - I note that it is 1999 all over again on iii! 10:36 John Hopkins Cancer Test "breakthrough"...i network This present news headline sounds like it depends on proteomics tests as well as genetic tests. I would think this could have significant impact on proteomic testing sales and services/ Why is this not affecting PRM share price?? ---------------------------------------------------------------------------------- 12:30 Hold Re: John Hopkins Cancer Test The Potter I also recently read an article on Sepsis, where biomarkers were found to give the best indication of the presence of this illness. I suppose that the share price Is unaffected by these news items, because many investors do not understand the possible implications, and those that do, are awaiting for news of profitability (promised in 2018). TP
harry vederci: lest we forget 'whats coming...' wasjobber 28 Jan '12 - 10:38 - 10840 of 75371 0 0 Thing that amuses me about all these bashers, is that they're trying to do the job that they're paid for well enough, but secretly loaded up to the eyeballs themselves with stock, bloody hilarious! Because they really would be stupid not to see whats coming now. bluemango 28 Jan '12 - 11:07 - 10841 of 75371 0 0 Just taking stock of where we are, the company recently came out with the comment that they had reached the ‘inflexion point’. Those familiar with Proteome will have heard similar phrases from the company over the years, so arguably we should not pay much attention to this one - and yet … it’s perhaps worth considering, now that by happy coincidence, Sanofi is finally coming to the end of its supply of shares to the market. To use another phrase familiar to this bb, people used to talk about getting all the ducks lined up in a row. Does that situation apply now? I believe so – and yes, we’ve heard it all before, but consider this: Firstly, don’t lose sight of the main and most valuable capabilities of the IP; a 90% accurate stroke biomarker panel, to diagnose stroke at point of care and in lab screening - a stroke deal was hoped to be signed by the end of 2011 and should not be far off now. Alzheimer’s biomarkers for diagnosis, prognosis and long-term monitoring – and for use in speeding up drug trials and saving millions of dollars in drug development costs. More significant still, candidate therapeutics for Alzheimer’s where the commercial value is enormous. Finally, data from the 1000 sample AD study are due, and indications are that the results will be exciting. People familiar with the ‘Prm story’ will have heard all sorts of speculation over the years of riches to come, while the share price has stayed lower than most people expected, alongside disappointing revenues. At this point some will genuinely not know what to believe any more and who can blame them? Part of this speculation has at its heart the thinking that it’s long been in CJP’s planning that he intended building the company’s IP to the point where a takeover was likely, with more than one willing bidder and a resulting high premium to the current share price. This is one part of the story that is hard to refute and, let’s face it; not an unusual ambition for any CEO – particularly in one with experience of building assets and profiting from their sale (Fitness First). Perhaps we’ll never know exactly why it has taken so long to deliver those lucrative biomarker licensing deals in stroke and Alzheimer’s, promised for so long but seemingly always ‘imminent̵7;. The jam tomorrow reputation has been justifiably acquired! There will no doubt be all sorts of explanations why the science has never been quite ready before, the partner companies being bogged down with legal niceties, or whatever else. I mention in passing, with reference to CJP’s game-plan as mentioned above, it’s been suggested the company is more valuable to a prospective buyer with the IP intact rather than tied up in licensing deals with competitor companies. It’s a view, but if so it would be a strategy that can only be sustained for so long, and then someone has to make a move. I believe we are at that point where a ‘move’ now has to take place, in the form of the first of the major biomarker deals, probably in stroke. If they can finally deliver a meaningful biomarker deal then perception is likely to radically change for the better and the company will at last start to gain more credibility in the wider market. It will then start to attract attention from some of the bigger players who will not want to lose out on possession of the IP. At around that point shareholders will need to keep a calm head and think about their own strategy. There will be all kinds of inducements and temptations to sell on any sharp upward movement, especially if and when the share price gets into higher territories not seen for years now. I have taken my own decision to align my interests with those of CJP and Cubana and to be guided by their aspirations and targets, and intend to hold through to the end-game. Eventually, the levels of around 240p reached back in late 2003 should not be ruled out of the possibilities, and even perhaps beyond that. Others will be more impatient, but they could risk missing out on premiums to the current price that would, as we stand today, sound impossible. There is also the question of capital gains. The ideal scenario would be an all-share offer from an acquirer, and a strategy for anyone with a significant holding could then be to keep the new shares for their dividend income, knowing each year there are also 10k of gains to be realised before tax. I would rather do this than pay considerable capital gains by selling shares in the market before then. These are only my own thoughts and they are aimed at shareholders who may not be in contact with others, and who rightly may well be confused by all the mixed messages, incessant bashing by some very determined characters, and expectations still not matched by delivery. I say to those holders that it’s worth keeping a cool head and having waited this long, just see this through and don’t be tempted to sell out too soon ‘if’ the price starts moving higher and you see things finally start to happen ….. Good luck all. And dyor. ps this bb is likely to get rather noisy in the coming weeks. The filter is going to be very useful ...
pools2: With Proteome Sciences now a GCLP accredited company, many many more doors are now open to them, which were firmly closed before. Do not underestimate the significance of the new accreditation and the additional business it will bring. PRM share price will go up and up from this current level. No additional funding will be needed and the company will be in profit next year.
tyum: BUY BUY BUY PRM share price is going up from here. Good news is coming. Buy at 4p while you can.
badger60: No they don't. People are far more interested about your cartel's intention to use questionable market manipulation to ramp up the PRM share price.......
dunderheed: Good evening gentlemen. Whilst we call await becoming millionaires in line with prm share price may I suggest a competition to guess the share price on 31.12.2017. I am coming kn with a possibly optimistic 54 gpb. I base this on a hypothesis that a deal it t/o is likely to happen with a large American company later in the year. I don't want to give too much away but I think the letters G and E are included in the name of company. All imho. Jt could you add this message to the header and maybe start a list of suggested share prices please? Thanks very much and have a Good night all.
saul goodman: This beaut is from 8 years ago to the day: (Name withheld in order to reduce acute embarrassment to anyone associated with the avatar) 9 May '09 - 09:48 - 47364 of 53733 0 0 PRM Summary - 8 May 09 [ Posted particularly to answer the question from MS MS regarding what happened on 13 Nov 2007?]. BACKGROUND. (This is a condensed summary of more than 50 pages of detailed research which I consider provides proof that the following explanation of the importance of 13 November 07 is correct.) We know, from the specific reference to strategic alliances in the Annual and Interim Reports in 2002, 2003 and 2004 and the related events beginning in the spring of 2003, that PRM had first a partnership with Amersham (for the Sensitizer, which was originally expected to make PRM profitable in 2003) and then a major strategic alliance (secret NDA) with GE which came into effect on completion of their takeover of Amersham in April 04. That strategic alliance resulted in GE taking over the commercialisation of PRM’s IP (in GE’s name) on the basis that GE would make a takeover offer - for which PRM would recommend acceptance – immediately PRM became profitable which was then confidently expected the following month. The price at which the takeover offer would be made would be based on GE’s standard formula for companies which had not yet become profitable – namely X3 the average share price over the preceding 3 years. That was arranged in December 2003 when the PRM share price was already well over £2 and expected to rise sharply before they became profitable and so to have resulted in a bid at the agreed value of around £5. But those plans were stymied in early May 04 by the ABI announcement of their iTRAQ which led to a patent issue which, in turn, led to the subsequent delays. That patent issue only became finally due to be settled on 13 November 2007 with the grant of the US TMT patent on that date. Meanwhile, the confident tone of PRM’s Reports suggested that GE has been making good progress with the commercialisation of PRMs IP. But PRM, bound by the secrecy clause in their strategic alliance NDA, was not (and is still not) allowed to announce details of that progress. In consequence the lack of real news (for several years) had resulted in the share price continuing at such a small fraction of PRM’s increasing value that (to protect its shareholders from a very low takeover price) PRM had no option but to delay PRM becoming profitable. Meanwhile, the progress on developing the value of PRM’s IP, with GE’s assistance, was steadily further increasing PRM’s value above that £5 level – as indicated on the PRM website with several products moving from “long term” towards “near term” and by the grant of the 350 patents etc mentioned in the PRM Reports. The planned TMT licence deal was with GE, who had already arranged a sub licence with Thermos Fisher (which had its origins in the deal being negotiated with Thermo Electron by Amersham in late 2003). That direct licence deal would have made PRM profitable on 13 November 2007 and triggered the agreed takeover offer bid. But the low share price meant that offer would have been below £2 per share compared with around the £5 per share originally agreed and intended - but which many shareholders would have accepted, even without PRM being compelled, by the original NDA, to recommend it. [Few shareholders seem to have taken advantage of the excellent estimates by xxxxxxx of the value to PRM of the various parts of its IP, or of the Summaries I posted of them. Many posters appear still to remain completely ignorant of where the share price should be in relation to PRM’s increasing value.] Around November 2007 our CEO, in a reported statement, assessed the value of PRM at nearly £14 per share. BUT because of his agreement to that takeover price formula in the original NDA, PRM would have had to recommend a takeover share price of under £2. That deal was NOT completed. .. WHY NOT? Our CEO was reported to have said that he hoped that shareholders would be pleased with the deal he had done instead It seems obvious that our CEO had managed to persuade GE to amend the original NDA to release PRM from GE’s stranglehold of the original takeover terms agreed four years previously – but still, I now believe, leaving the PROFITABILITY deadline in place to trigger the BIG announcement I have forecast. ----------------------- That, MS MS, is the answer to your question. Events on 12/13 November 2007 dramatically altered the future for us shareholders. We are now assured of a takeover at a price at least £5 per share and probably nearer double that. Meanwhile, as I have already recently posted, the loan conversion provides the directors with the potential ability to hold 29.74% (FD by all options etc) which together with friends appears to amount to around 53% control of PRM. That means that our CEO can now dictate the takeover terms and has a poison pill against low bids. As regards PRM’s finances, anyone who thinks there is, or ever has been, any real problem needs their head examined. You may perhaps ask: “What was that deal that our CEO did with GE?” To anyone who has not done very detailed research on all the events over the last seven years, it may be difficult to guess. But the recent amendments to the PRM website have, as I recently posted, confirmed that my guess about that new deal has been correct. But I do not think that PRM and GE would like it publicised at this time. I will however point out that (as is indicated by PRM apparently not even yet accepting the full down payment on signature from the TF) PRM appear STILL to be doing their best to delay becoming profitable. That accounts for the delays of the last many months – during which the PRM value has continued increasing since his reported statement. The future for PRM looks brilliant I confidently repeat that I believe £5 per share is now a guaranteed minimum. I again confirm that none of my information on which I base all the above has come from either GE or PRM – other then what has been already in the public domain. I also stress that all above is IMO and that you must DYOR Regards to all LTHs, xxxxx PS Edited 25 June 09.
ih_433513: Richard won't be playing as he's been saying for years that there's no need for any further fund raisings - the company can survive on fresh air alone forever. One day of course he might be right about something but as he's already an octogenarian the odds are pretty unlikely. The Dawsons were of course rather poor runner ups to the Barkers in the final of Ask the Family back in the 70s. There's a pic of the dapper family in the link - I think he's the guy on the right - and the tragic final score is shown at the bottom of the link. I gather the runners up all got mugs with their names engraved on them. He probably still chokes on his coffee from that mug every morning when he turns on the teletext to see the PRM share price. hxxp://
golly blackwell: Indeed and who can ever (or would want to) forget bullsh1t like this, that was his stock in trade. 28-04-08 The future PRM.L 6 About three years ago a friend of mine “x” who works in the city advised me to buy PRM. Another friend of mine “y” (who is a scientist and understands what the company are doing) did likewise. We have not been at all pleased with the result. But then, immediately the Thermos Fisher deal was announced “x” rang up both me and “y” and urged us to buy more – which we did. Feeling very fed up with the result, I yesterday persuaded “x” to come and explain to us both what the hell was happening and why he had been so wrong. The result is that we all will be buying more – on the basis that we believe we shall make 10 – 20 times our money in the coming weeks or months. “x” explained that the fall in the share price was mainly due to a remarkable coincidence, The manager of a fund had been sacked around that time and all the shares held by his organisation had been thrown onto the market simultaneously – not only nearly three million of PRM but all the others they had held of similar companies too. It was that, probably helped by a certain stockbroker firm and other bashers and the market generally, that had caused the fall. Otherwise he felt sure that the price would have gone strongly north. “y”, my scientist friend, and “x” then had a lengthy discussion about the future prospects for PRM. Not being technical, I listened intently to the reasons why they thought the share price could multiply by 20 and summarise my understanding as follows. As soon as the big seller is finished (which they thought was likely very soon now) the price should start recovering – because it is such an obvious “buy” as indicated by Blue Oar and Landsbanki on the TMT deal alone – particularly when they wake up to the even greater value of some of the other IP owned by PRM. Alzheimer’s, on which “x” said a deal was done with Amersham/GE in April 04, appears to be making excellent progress and could become extremely valuable. HIV/AIDS, in which Intronn now has an interest in the cure being developed by VIRxSYS could be worth even more to PRM, and the SMaRT technology seems to be going ahead well. Cancers. Although promised, we have never had more information on the JY announced nearly four years ago. HTS. We have not been informed of any failure on the tests and can therefore expect the forecast licence deals with around 20 companies to be announced soon. ProteoShop. Enormous potential value and already generating increasing revenue. vCJD. Now believed to be “near term”. Sanofi. A possible bonus of up to £23 million. Meanwhile, it seems almost certain that PRM will become a profitable company this year. A point they made is that everyone seems to be concentrating on the figures missing from the TMT dead and ignoring the broader picture. A takeover, in due course, seems inevitable – perhaps with different companies bidding for different parts of the IP such as the Intronn holding. I asked whether PRM had a collaboration agreement with GE and whether GE would take them over. “x” said that Amersham did have an agreement to make a takeover offer for PRM under certain conditions in late 03, which GE took over in April 04, but that that agreement was cancelled last year. Until then GE had been helping (handling) the commercialisatin of PRM's IP. They discussed whether TF might now want to take PRM over. Both “x” and “y” are confident that there will soon be an announcement which will indicate the enormous value of PRM’s IP, and the other companies involved – for example with the JV for the cancers. I now share their optimism that we are on to a 10 – 20 bagger. I am not technical enough, or sufficiently well informed, to answer questions on the above. I am merely reporting my understanding of what they indicated. ________________________________________
stocktastic: peverill 'look at the price over the last few weeks' there's a pending fundraiser I don't believe there is anything worsened at the company - things remain on track for 2016 and beyond. Stroke was delayed and TauRx generated results that have reduced expectations from CK1d. Later starting H1 contracts also meant the H1 growth was not as great as it would have been. As I have suggested several times a) what has materially worsened since pre-results? The revenue growth and cash burn decrease was in line with any expectations I have seen posted, including my own b) what do you suggest has 'gone wrong' over the last few weeks. The simple answer is that we have always been at the mercy of a fundraiser if a CK1d deal didn't come through/ if expectations of that weren't high. melodrama 'The share price of PRM and the volume which accompanies said share price moves is all that matters, short and long term.' You are talking nonsense and missing the point. A short term share price does not matter to most as I said. The reason being that this is not a high liquidity traders stock. If PRM moves to profitability, then the share price will find a new level, whatever it is this week. The price right now does not (other than dilutive impact in a fundraiser etc) affect what price will be seen a year from now. In light of that, it would seem that you're the one being naive. I don't support the board particularly and have long been critical of CJP and others, so your remarks are daft. In terms of Haigh, I see no reason to criticise him before giving a chance to do what he is setting out to do. What you miss, is that the company is no worse than when Haigh came in. The share price does not reflect the company, because the market does not know the company's outlook. I posted views to Pram before the results and he would be able to confirm that the way I saw the company then, is exactly as I see it now. The reality is that a few others have come around to that understanding. To give one quote 'The business is actually doing ok. It's more that slow and steady growth isn't what most want and until we're profitable, there'll be fundraisers.' You remark about views on PRM's strategies, but I'm not sure you necessarily get what it has been that PRM was trying to do and why. I've always felt Sens-It-Iv was a no hoper and explained to CJP that the volumes of animal testing were insignificant... that the pharma side of that would need too much validation. At the same time though, one can see that Sens-It-Iv was largely grant funded and that partners were hoped to take products to the next stages. Haigh seems to be doing the right thing - focusing on the projects that can generate returns. Cutting costs elsewhere. If you don't understand my views, then I suggest you may not understand the company or its projects enough. Still, you're welcome to provide rational explanations and we can see if those hold up.
Proteome share price data is direct from the London Stock Exchange
add chat code
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20180623 02:21:47